AUSAF (Australis Capital) EBITDA Margin %: -169.98% (As of Dec. 2021)

What is Australis Capital EBITDA Margin %?

Australis Capital AUSAF -95.00% EBITDA Margin % is -169.98% as of Dec. 2021.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Australis Capital's EBITDA for the three months ended in Dec. 2021 was $-3.15 Mil. Australis Capital's Revenue for the three months ended in Dec. 2021 was $1.85 Mil. Therefore, Australis Capital's EBITDA margin for the quarter that ended in Dec. 2021 was -169.98%.

Australis Capital (OTCPK:AUSAF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Australis Capital EBITDA Margin % Related Terms

Australis Capital EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Australis Capital's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australis Capital EBITDA Margin % Chart

Australis Capital Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

EBITDA Margin %

0.00

-3,173.20

-10,220.89

-3,439.65

Australis Capital Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
EBITDA Margin %	Get a 7-Day Free Trial														-21,321.43	692.88	-527.93	-170.50	-169.98

AUSAF vs ZTS, CTLT, VTRS: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Australis Capital EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Australis Capital's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Australis Capital's EBITDA Margin % falls into.

Save Embed

Australis Capital EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Australis Capital's EBITDA Margin % for the fiscal year that ended in Mar. 2021 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2021 )	/	Revenue (A: Mar. 2021 )
	=	-19.606	/	0.57
	=	-3,439.65 %

Australis Capital's EBITDA Margin % for the quarter that ended in Dec. 2021 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2021 )	/	Revenue (Q: Dec. 2021 )
	=	-3.148	/	1.852
	=	-169.98 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -169.98% mean?

Australis Capital (AUSAF) has a EBITDA Margin % of -169.98% as of Dec. 2021. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Australis Capital and its competitors.

Is Australis Capital's EBITDA Margin % too high?

Australis Capital's current EBITDA Margin % is -169.98%.

How does Australis Capital's EBITDA Margin % compare to ZTS and CTLT?

Australis Capital's EBITDA Margin % of -169.98% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Australis Capital and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current EBITDA Margin % is -169.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Australis Capital stock overvalued right now?

Australis Capital (AUSAF) has a current EBITDA Margin % of -169.98%. The current EBITDA Margin % is -169.98%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Australis Capital (AUSAF), the current EBITDA Margin % is -169.98% as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Australis Capital Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies TSXV:FLWR TSX:AVCN XCNQ:CPTR NEOE:FH TSX:LABS XCNQ:VIBE XCNQ:CLC XCNQ:YOUR TSX:VIVO XCNQ:NVG XTER:MRK ZTS TSE:4502 NSE:SUNPHARMA CTLT TSE:4507 SHSE:600196 SZSE:000538 VTRS NSE:DIVISLAB

Address 376 E. Warm Springs Road, Suite 190, Las Vegas, NV, USA, 89119

Website https://ausa-corp.com

Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.